We emphasize the importance of shared decision making and frequent follow-up in the use of GH therapy in patients with congenital contractures and the importance of further research in assessing the long-term outcomes of GH therapy in patients with coexisting panhypopituitarism and arthrogryposis. This evidence concerns the gene GH1 and panhypopituitarism.